Skip to main navigation Skip to search Skip to main content

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 (IND #78,416) in Combination with Pegylated Liposomal Doxorubicin (Doxil) in Patients with Recurrent of Persistent Epithelial Ovarian, Fallopian Tube or Primary . . .

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date07/9/13 → 07/8/16

Funding

  • VentiRx Pharmaceuticals Incorporated: $65,115.58